Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT1 | P17948 | 5/20 | 0.66 |
| ▸ | FLT4 | P35916 | 5/20 | 0.66 |
| ▸ | KDR | P35968 | 5/20 | 0.66 |
| ▸ | IMPDH2 | P12268 | 10/20 | 0.53 |
| ▸ | VCP | P55072 | 3/20 | 0.47 |
| ▸ | SIRT7 | Q9NRC8 | 1/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5480372 | 0.91 | FLT1 (0.69) | FLT1FLT4KDRIMPDH2VCP | |
| SCHEMBL5319878 | 0.86 | FLT1 (0.76) | FLT1FLT4KDRIMPDH2VCP | |
| SCHEMBL5464876 | 0.84 | FLT1 (0.77) | FLT1FLT4KDRIMPDH2VCP | |
| SCHEMBL5469587 | 0.81 | KDR (0.76) | FLT1FLT4KDRIMPDH2VCP | |
| SCHEMBL5480404 | 0.81 | KDR (0.97) | FLT1FLT4KDRIMPDH2VCP | |
| SCHEMBL5477700 | 0.79 | KDR (0.76) | FLT1FLT4KDRIMPDH2VCP | |
| SCHEMBL5475168 | 0.77 | KDR (0.79) | FLT1FLT4KDR | |
| SCHEMBL5469678 | 0.76 | FLT1 (0.68) | FLT1FLT4KDRIMPDH2VCP | |
| SCHEMBL5316678 | 0.76 | FLT1 (0.60) | FLT1FLT4KDRIMPDH2VCP | |
| SCHEMBL5319618 | 0.75 | FLT1 (0.59) | FLT1FLT4KDRIMPDH2VCP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050288515-A1 | Chemical compounds | SMITHLINE BEECHAM CORPORATION | 2005-12-29 | — | — | US | claimed |
| US-20070142437-A1 | CHEMICAL COMPOUNDS | BROWN MATTHEW L | 2007-06-21 | — | — | US | disclosed |
| US-20070142437-A1 | CHEMICAL COMPOUNDS | BROWN MATTHEW L | 2007-06-21 | — | — | US | disclosed |
| US-20070142437-A1 | CHEMICAL COMPOUNDS | BROWN MATTHEW L | 2007-06-21 | — | — | US | disclosed |
| US-7189712-B2 | 1,3-Oxazole compounds for the treatment of cancer | SMITHKLINE BEECHAM CORPORATION (US) | 2007-03-13 | — | — | US | disclosed |
| US-7189712-B2 | 1,3-Oxazole compounds for the treatment of cancer | SMITHKLINE BEECHAM CORPORATION (US) | 2007-03-13 | — | — | US | disclosed |
| US-7189712-B2 | 1,3-Oxazole compounds for the treatment of cancer | SMITHKLINE BEECHAM CORPORATION (US) | 2007-03-13 | — | — | US | disclosed |
| US-20050288515-A1 | Chemical compounds | SMITHLINE BEECHAM CORPORATION | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142437-A1 | CHEMICAL COMPOUNDS | CDK4, CDK2, CDK3 | FLT1 56/4885FLT4 47/4885KDR 33/4885 |
| US-20050288515-A1 | Chemical compounds | CDK4, CDK2, CDK3 | FLT1 56/4885FLT4 47/4885KDR 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.